Abstract
Antihypertensive therapy has been well established to reduce hypertension-related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was designed to determine whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular disease events in essential hypertensives in Japan. Registration, randomization and data entry were performed over the Internet. The minimization method (to control for age, gender, blood pressure level and history) was used at random assignment to ensure that the background factors were equivalent between the groups at baseline. After the registration, patients were followed-up for cardiovascular events (primary endpoints), echocardiography, 123I-metaiodobenzylguanidine (MIBG) imaging, laboratory tests and blood pressure for 3 years. Currently, 797 patients have been enrolled and assigned to two groups: a valsartan (n=399) and an amlodipine (n=398) group. At baseline, controlled factors (age, gender, blood pressure level, and left ventricular hypertrophy) and the proportions of patients with diabetes and hyperlipidemia were equally allocated. At 12 months, both drugs evenly and significantly lowered blood pressure to the target level (valsartan: 133/79 mmHg; amlodipine: 132/79 mmHg). In conclusion, by combining the data on cardiovascular events with the results of echocardiographic, radionuclide imaging, and blood/urine studies, the VART study will provide mechanistic insights into the clinical outcomes and treatment effects of the trial. (Hypertens Res 2008; 31: 21−28)
Similar content being viewed by others
Article PDF
References
Chobanian AV, Bakris GL, Black HR, et al : The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Wing LM, Reid CM, Ryan P, et al : A comparison of outcomes with angiotensin-converting−enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–592.
Dahlof B, Devereux RB, Kjeldsen SE, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Lindholm LH, Ibsen H, Dahlof B, et al : Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–1010.
Viberti G, Wheeldon NM : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure−independent effect. Circulation 2002; 106: 672–678.
Wright JT Jr, Bakris G, Greene T, et al : Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421–2431.
Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R : Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004; 17: 222–229.
Ishimitsu T, Kameda T, Akashiba A, et al : Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. Hypertens Res 2005; 28: 865–870.
Pitt B, Segal R, Martinez FA, et al : Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–752.
Pitt B, Poole-Wilson P, Segal R, et al : Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study—ELITE II. J Card Fail 1999; 5: 146–154.
Pitt B, Poole-Wilson PA, Segal R, et al : Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587.
Dickstein K, Kjekshus J : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–760.
Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A : Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5: 155–160.
Cohn JN, Tognoni G : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.
Weber MA, Julius S, Kjeldsen SE, et al : Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906.
Hansson L, Lindholm LH, Ekbom T, et al : Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–1756.
Tuomilehto J, Rastenyte D, Birkenhager WH, et al, Systolic Hypertension in Europe Trial Investigators : Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677–684.
Liu L, Wang JG, Gong L, Liu G, Staessen JA, Systolic Hypertension in China (Syst-China) Collaborative Group : Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823–1829.
Kuwajima I, Kuramoto K, Ogihara T, et al : Tolerability and safety of a calcium channel blocker in comparison with a diuretic in the treatment of elderly patients with hypertension: secondary analysis of the NICS-EH. Hypertens Res 2001; 24: 475–480.
Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M, The Amlodipine Cardiovascular Community Trial Study Group : Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1996; 77: 713–722.
Spratt KA : Sex- and age-related antihypertensive effects of amlodipine. Am J Cardiol 1997; 79: 843–844.
Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ED, Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents : Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med 1999; 159: 551–558.
Guidelines Subcommittee : 1999 World Health Organization−International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151–183.
Staessen JA, Wang JG, Thijs L : Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305–1315.
Douglas JG, Thibonnier M, Wright JT Jr : Essential hypertension: racial/ethnic differences in pathophysiology. J Assoc Acad Minor Phys 1996; 7: 16–21.
Flack JM, Ensrud KE, Mascioli S, et al : Racial and ethnic modifiers of the salt-blood pressure response. Hypertension 1991; 17: I115–I121.
Mtabaji JP, Moriguchi Y, Nara Y, Mizushima S, Mano M, Yamori Y : Ethnic differences in salt sensitivity: genetic or environmental factors? Clin Exp Pharmacol Physiol Suppl 1992; 20: 65–67.
Rutledge DR : Race and hypertension. What is clinically relevant? Drugs 1994; 47: 914–932.
Ogihara T, Saruta T, Matsuoka H, et al : Valsartan in elderly isolated systolic hypertension (VALISH) study: rationale and design. Hypertens Res 2004; 27: 657–661.
Mochizuki S, Dahlof B, Shimizu M, et al : Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–1439.
Khor GL : Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 2001; 10: 76–80.
Kuwahara T, Hamada M, Hiwada K : Direct evidence of impaired cardiac sympathetic innervation in essential hypertensive patients with left ventricular hypertrophy. J Nucl Med 1998; 39: 1486–1491.
Sakata K, Shirotani M, Yoshida H, Kurata C : Cardiac sympathetic nervous system in early essential hypertension assessed by 123I-MIBG. J Nucl Med 1999; 40: 6–11.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nakayama, K., Kuwabara, Y., Daimon, M. et al. Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results. Hypertens Res 31, 21–28 (2008). https://doi.org/10.1291/hypres.31.21
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.21